SlideShare a Scribd company logo
HIVHIV
((HHUMANUMAN IIMMUNODEFICIENCYMMUNODEFICIENCY VVIRUS)IRUS)
Kebanyakan ilmuwan meyakini bahwa AIDS
berasal dari Afrika Sub-Sahara selama abad ke-20
kini penyakit pandemik AIDS
diperkiraan telah menginfeksi 38,6 juta orang
di seluruh dunia.
Pada Januari 2006, UNAIDS sebagai badan PBB
yang menangani penanggulangan penyakit AIDS dan HIV
(Joint United Nations Programme on HIV/AIDS)
bekerjasama dengan WHO (World Health Organization), badan PBB
untuk kesehatan dunia,
memperkirakan AIDS telah membunuh lebih dari 25 juta orang
sejak pertama kali diakui pada tanggal 5 Juni 1981.
Oleh karena itu, penyakit ini merupakan salah satu wabah
paling mematikan dalam sejarah.
Pita Merah terlipat sebagai simbol solidaritas
untuk orang yang positif terinfeksi virus HIV dan AIDS.
The proteins gp120 and gp41 together
make up the spikes that project from HIV particles,
while p17 forms the matrix and p24 forms the core.
Inside the core are three enzymes required for HIV replication called
reverse transcriptase, integrase and protease.
How can we prove that HIV causes AIDS?
Koch's Postulates
In the nineteenth century, the German scientist Robert Koch developed
a set of four "postulates" to guide people trying to prove that a germ causes a disease.
Scientists agree that if HIV satisfies all of these conditions with regard to AIDS
then it must be the cause of AIDS:12
Koch 1: The germ must be found in every person with the disease
Koch 2: The germ must be isolated from someone who has the disease
and grown in pure culture
Koch 3: The germ must cause the disease when introduced
into a healthy person
Koch 4: The germ must be re-isolated from the infected person
DESKRIPSIDESKRIPSI
•HIV termasuk golongan Retrovirus
•Mula-mula dikenal sebagai LAV (Lymphadenopathy Associated Virus),
kemudian dikenal sebagai HTLV-III (Human T cell Lymphotropic Virus)
dan akhirnya disebut sebagai HIV (Human Immunodeficiency Virus)
How many genes does HIV have?
•HIV has just nine genes
(compared to more than 500 genes in a bacterium,
and around 20,000-25,000 in a human).
•Three of the HIV genes, called gag, pol and env,
contain information needed to make structural proteins
for new virus particles.
•The other six genes, known as tat, rev, nef, vif, vpr and vpu,
code for proteins that control the ability of HIV to infect a cell,
produce new copies of virus, or cause disease.
What is the difference between HIV-1 and HIV-2?
There are two types of HIV: HIV-1 and HIV-2.
Both types are transmitted by sexual contact, through blood,
and from mother to child,
and they appear to cause clinically indistinguishable AIDS.
However, it seems that HIV-2 is less easily transmitted,
and the period between initial infection
and illness is longer in the case of HIV-2.
How many subtypes of HIV-1 are there?
This diagram illustrates the different levels of HIV classification.
Each type is divided into groups, and each group is divided into subtypes and CRFs.
Are there differences in transmission?
It has been observed that certain subtypes/CRFs
are predominantly associated with specific modes of transmission.
In particular, subtype B is spread mostly by homosexual contact
and intravenous drug use (essentially via blood),
while subtype C and CRF A/E tend to fuel heterosexual epidemics
(via a mucosal route).
UNIQUE CHARASTERISTICS OFUNIQUE CHARASTERISTICS OF
RETROVIRUSRETROVIRUS
•Virus has enveloped spherical virion that is 80 to 120 nm in diameter and that
encloses a capsid containing two copies of the positive-strand RNA genome
•RNA dependent DNA polymerase (reverse transcriptase) and integrase enzymes
are carried in the virion
•Virus receptor is the initial determinant of tissue tropism
•Replication proceeds through a DNA intermediate termed the provirus
•The provirus integrates randomly into the host chromosome and becomes
a celluler gene
In this computer generated image,
the large object is a human CD4+ white blood cell,
and the spots on its surface and
the spiky blue objects in the foreground represent HIV particles.
This electron microscope photo shows newly
formed HIV particles budding from a human cell.
DEFINISIDEFINISI AIDSAIDS
Penyakit akibat menurunnya daya tahan tubuh
yang didapat karena infeksi HIV
KLASIFIKASI INFEKSIKLASIFIKASI INFEKSI AIDSAIDS
•Kelompok I :Infeksi Akut
•Kelompok II :Infeksi kronik asimptomatik
•Kelompok III :PGL (Persistent Generalized Lymphadenopathy)
•Kelompok IV :Penyakit lain :
- Penyakit Neurologis
- Penyaakit infeksi sekunder
- Keganasan sekunder
GEJALA KLINIKGEJALA KLINIK
Gejala mayor:
•Berat badan menurun lebih dari 10 % dalam 1 bulan
•Diare kronis yang berlangsung lebih dari 1 bulan
•Demam berkepanjangan lebih dari 1 bulan
•Penurunan kesadaran dan gangguan neurologik
•Demensia/HIV ensefalopati
Gejala minor:
•Batuk menetap lebih dari 1 bulan
•Dermatitis generalisata
•Adanya herpes zoster muli segmental dan herpes zoster berulang
•Kandidiasis Orofaringeal
•Herpes Simpleks kronis progresif
•Limfadenopati generalisata
•Infeksi jamur berulang pada alat kelamin wanita
•Retinitis virus sitomegalo
When to Start Therapy
Clinical Category CD4+ Count Viral Load Recommendation
Symptomatic (AIDS
or
severe symptoms)
Any value Any value Treat
Asymptomatic,
AIDS
CD4+ < 200/mm3
Any value Treat
Asymptomatic
CD4+ > 200/mm3
but < 350/mm3 Any value
Offer treatment, but
controversial †
Asymptomatic CD4+ > 350/mm3
> 100,000 c/mL
Consider therapy
or observe † (Data
inconclusive for
either alternative)
Asymptomatic CD4+ > 350/mm3
< 100,000 c/ml
Defer therapy and
observe
•There are special considerations for pregnant women; consult Pregnancy Tables 1-3
† Patient readiness, probability of adherence, and prognos based on CD4 count
and HIV load need to be considered
Adult ART Table 1.  
HIV and AIDS in the United Kingdom, 1990-2001
.
HIV and AIDS in Thailand, 1984-2000
DEFINISI KASUS DEWASADEFINISI KASUS DEWASA
Seorang dewasa (>12 tahun) dianggap AIDSSeorang dewasa (>12 tahun) dianggap AIDS
apabila menunjukkan tes HIV positif denganapabila menunjukkan tes HIV positif dengan
strategi pemeriksaan yang sesuai dengan se-strategi pemeriksaan yang sesuai dengan se-
kurang2nya didapatkankurang2nya didapatkan
2 gejala mayor2 gejala mayor dandan
1 gejala minor1 gejala minor,,
dan gejala ini bukan disebabkandan gejala ini bukan disebabkan
oleh keadaan lain yang tidak berkaitanoleh keadaan lain yang tidak berkaitan
dengan infeksi HIVdengan infeksi HIV
DEFINISI KASUS ANAKDEFINISI KASUS ANAK
 Anak umur lebih dari 18 bulan,menunjukkan tes HIV positif,Anak umur lebih dari 18 bulan,menunjukkan tes HIV positif,
dan sekurang-kurangnya didapatdan sekurang-kurangnya didapat
-2 gejala mayor dan 2 gejala minor dibawah ini dengan ibu-2 gejala mayor dan 2 gejala minor dibawah ini dengan ibu
HIV positif, dan gejala tersebut bukan disebabkan olehHIV positif, dan gejala tersebut bukan disebabkan oleh
keadaan lain yang tidak berkaitan dengan infeksi HIVkeadaan lain yang tidak berkaitan dengan infeksi HIV
 Anak umur 18 bulan atau kurang, ditemukanAnak umur 18 bulan atau kurang, ditemukan
-2 gejala mayor yang-2 gejala mayor yang berkaitanberkaitan dan 2 gejala minor dengandan 2 gejala minor dengan
ibu HIV positif, dan gejala tersebut bukan disebabkan olehibu HIV positif, dan gejala tersebut bukan disebabkan oleh
keadaan lain yang tidak berkaitan dengan infeksi HIVkeadaan lain yang tidak berkaitan dengan infeksi HIV
GEJALA MAYOR
• Berat badan menurun atau gagal tumbuh
•Diare terus menerus atau berulang dalam waktu lebih 1 bulan
•Demam terus menerus atau berulang > 1 bulan
•Infeksi saluran pernafasan bagian bawah yang parah atau menetap
GEJALA MINOR
•Limfadenopati generalisata atau hepatosplenomegali
•Kandidiasis oral
•Infeksi bakteridan/virus yang berulang
•Batuk kronis
•Dermatitis yang luas
•Ensefalitis
CARA PENULARANCARA PENULARAN
1. Hubungan seksual
2. Kontak langsung dengan darah/
produk darah/ jarum suntik
3.Vertikal
GOLONGAN RESIKO TINGGIGOLONGAN RESIKO TINGGI
1. Sering berganti pasangan seksual
2. PMS (Penyakit Menular Seksual Wanita Tuna Susila
3. Penyalahgunaan obat (pemakai narkoba suntikan)
PEMERIKSAAN LABORATORIUM IPEMERIKSAAN LABORATORIUM I
(spesifik HIV)(spesifik HIV)
•Dipstick
•ELISA
•Western Blot: p24, gp41, gp 120
•RT-PCR
PEMERIKSAAN LABORATORIUM IIPEMERIKSAAN LABORATORIUM II
1. Pemeriksaan laboratorium dasar
•Pemeriksaan darah lengkap, termasuk hitung jenis
•Tes faal ginjal
•Tes faal hepar
2. Menentukan tahapan infeksi
•Jumlah CD4 atau persentase limfosit atau viral load
3. Pemeriksaan Tambahan
•Foto toraks
•VDRL
•IgG anti Toxoplasma
•HBsAg/anti HBs/HBcAg, anti HCV
Such measurements can be made using PCR,
branched-DNA signal-amplification (bDNA)
or quantitative microculture techniques.
For example, the table below shows just how useful bDNA forecasts can be:68
Viral load (RNA copies per
millilitre of blood plasma)
Proportion of patients developing
AIDS within six years
less than 500 5.4%
501-3,000 16.6%
3,001-10,000 31.7%
10,001-30,000 55.2%
more than 30,000 80.0%
The immune deficiency definition of AIDS requires
a CD4+ cell count consistently
below 200 cells per cubic millimetre of blood,
which cannot be explained by any factor other than HIV
(such as cancer, malnutrition, radiation or chemotherapy).
•treatment of adults and adolescents
•treatment of children
•treatment of pregnant women and prevention
of mother-to-child transmission of HIV
•prevention of opportunistic infections
Treatment
Opportunistic infections:
Infections that usually don't cause disease in people
with normal immune systems,
but can affect people with damaged immune systems,
including people with HIV.
Topics covered in the guidelines include:
•the goals of anti-HIV therapy
•when to start treatment
•monitoring of patient health
•medication side effects and their management
•anti-HIV medications for use during pregnancy
•diagnosis of HIV infection in infants
Antiretroviral Agents Currently Available (generic name/Trade name)
Nucleoside Analogs
zidovudine/Retrovir (AZT, ZDV)
didanosine/Videx, Videx EC (ddI)
zalcitabine/HIVID (ddC)
stavudine/Zerit (d4T)
lamivudine/Epivir (3TC)
abacavir/Ziagen (ABC)
Non-Nucleoside Reverse Transcriptase Inhibitors
nevirapine/Viramune (NVP)
delavirdine/Rescriptor (DLV)
efavirenz/Sustiva (EFV)
Nucleotide Analogue
tenofovir DF/Viread (TDF)
Protease Inhibitors
indinavir/Crixivan
ritonavir/Norvir
saquinavir/Invirase, Fortovase
nelfinavir/Viracept
amprenavir/Agenerase
lopinavir/ritonavir, Kaletra
Terima Kasih !Terima Kasih !
Hiv

More Related Content

What's hot

PRESENTATION kondiloma akuminata
PRESENTATION kondiloma akuminataPRESENTATION kondiloma akuminata
PRESENTATION kondiloma akuminata
SK Sulistyaningrum
 
Chikungunya
ChikungunyaChikungunya
Chikungunya
DR Irene
 
Materi iii tatalaksana gizi buruk
Materi iii tatalaksana gizi burukMateri iii tatalaksana gizi buruk
Materi iii tatalaksana gizi buruk
Joni Iswanto
 
Sifilis. bag. 13
Sifilis. bag. 13Sifilis. bag. 13
Sifilis. bag. 13
tristyanto
 

What's hot (20)

soal osce comprehensive
soal osce comprehensivesoal osce comprehensive
soal osce comprehensive
 
Abses hepar
Abses heparAbses hepar
Abses hepar
 
Presentasi morbus hansen
Presentasi morbus hansenPresentasi morbus hansen
Presentasi morbus hansen
 
Ppt DBD
Ppt DBDPpt DBD
Ppt DBD
 
PRESENTATION kondiloma akuminata
PRESENTATION kondiloma akuminataPRESENTATION kondiloma akuminata
PRESENTATION kondiloma akuminata
 
Infeksi Menular Seksual (IMS)
Infeksi Menular Seksual  (IMS)Infeksi Menular Seksual  (IMS)
Infeksi Menular Seksual (IMS)
 
Chikungunya
ChikungunyaChikungunya
Chikungunya
 
Status Dermatologikus
Status DermatologikusStatus Dermatologikus
Status Dermatologikus
 
Mandala of health paul
Mandala of health   paulMandala of health   paul
Mandala of health paul
 
Tumor Jinak Ginekologi
Tumor Jinak GinekologiTumor Jinak Ginekologi
Tumor Jinak Ginekologi
 
Aki
AkiAki
Aki
 
Materi iii tatalaksana gizi buruk
Materi iii tatalaksana gizi burukMateri iii tatalaksana gizi buruk
Materi iii tatalaksana gizi buruk
 
Tkk7
Tkk7Tkk7
Tkk7
 
Sifilis. bag. 13
Sifilis. bag. 13Sifilis. bag. 13
Sifilis. bag. 13
 
Ekspertise Trombositosis Esensial
Ekspertise Trombositosis EsensialEkspertise Trombositosis Esensial
Ekspertise Trombositosis Esensial
 
ITP (IDIOPATIK THROMBOSITOPENIK PURPURA)
ITP (IDIOPATIK THROMBOSITOPENIK PURPURA)ITP (IDIOPATIK THROMBOSITOPENIK PURPURA)
ITP (IDIOPATIK THROMBOSITOPENIK PURPURA)
 
modul 3 BAB berdarah
modul 3 BAB berdarahmodul 3 BAB berdarah
modul 3 BAB berdarah
 
Hiv aids
Hiv aidsHiv aids
Hiv aids
 
Penatalaksanaan Lupus Eritematosus Sistemik
Penatalaksanaan Lupus Eritematosus SistemikPenatalaksanaan Lupus Eritematosus Sistemik
Penatalaksanaan Lupus Eritematosus Sistemik
 
Case Report diare Akut Dehidrasi Ringan Sedang ppt
Case Report diare Akut Dehidrasi Ringan Sedang pptCase Report diare Akut Dehidrasi Ringan Sedang ppt
Case Report diare Akut Dehidrasi Ringan Sedang ppt
 

Viewers also liked

Reaksi terhadap agen fisika dan agen kimia
Reaksi terhadap agen fisika dan agen kimiaReaksi terhadap agen fisika dan agen kimia
Reaksi terhadap agen fisika dan agen kimia
riski albughari
 
Vektor penyakit protozoa
Vektor penyakit protozoaVektor penyakit protozoa
Vektor penyakit protozoa
riski albughari
 
Pembiakan dan asal virus
Pembiakan dan asal virusPembiakan dan asal virus
Pembiakan dan asal virus
riski albughari
 
3 komplikasi transfusi darah
3 komplikasi transfusi darah3 komplikasi transfusi darah
3 komplikasi transfusi darah
riski albughari
 
6 pencatatan & pelapoan bdrs (dr. neni )
6 pencatatan & pelapoan bdrs (dr. neni )6 pencatatan & pelapoan bdrs (dr. neni )
6 pencatatan & pelapoan bdrs (dr. neni )
riski albughari
 
4 keamaman kerja di bdrs
4 keamaman kerja di bdrs4 keamaman kerja di bdrs
4 keamaman kerja di bdrs
riski albughari
 
3 fungsi dan tugas utd & bdrs
3 fungsi dan tugas utd & bdrs3 fungsi dan tugas utd & bdrs
3 fungsi dan tugas utd & bdrs
riski albughari
 
Vektor penyakit cacing (filariasis)
Vektor penyakit cacing (filariasis)Vektor penyakit cacing (filariasis)
Vektor penyakit cacing (filariasis)
riski albughari
 
5b manajemen perawatan dan kalibrasi alat 1
5b manajemen perawatan dan kalibrasi alat 15b manajemen perawatan dan kalibrasi alat 1
5b manajemen perawatan dan kalibrasi alat 1
riski albughari
 
Vektor penyakit virus, riketsia, dan bakteri
Vektor penyakit virus, riketsia, dan bakteriVektor penyakit virus, riketsia, dan bakteri
Vektor penyakit virus, riketsia, dan bakteri
riski albughari
 
Morfologi, daur hidup, perilaku nyamuk
Morfologi, daur hidup, perilaku nyamukMorfologi, daur hidup, perilaku nyamuk
Morfologi, daur hidup, perilaku nyamuk
riski albughari
 

Viewers also liked (19)

2 menulis pks
2 menulis pks2 menulis pks
2 menulis pks
 
Serologi
SerologiSerologi
Serologi
 
Presentasi h5 n1 short
Presentasi h5 n1 shortPresentasi h5 n1 short
Presentasi h5 n1 short
 
Replikasi virus
Replikasi virusReplikasi virus
Replikasi virus
 
Penggolongan virus
Penggolongan virusPenggolongan virus
Penggolongan virus
 
Entomologi kedokteran
Entomologi kedokteranEntomologi kedokteran
Entomologi kedokteran
 
Reaksi terhadap agen fisika dan agen kimia
Reaksi terhadap agen fisika dan agen kimiaReaksi terhadap agen fisika dan agen kimia
Reaksi terhadap agen fisika dan agen kimia
 
Vektor penyakit protozoa
Vektor penyakit protozoaVektor penyakit protozoa
Vektor penyakit protozoa
 
Vektor mekanik
Vektor mekanikVektor mekanik
Vektor mekanik
 
Pembiakan dan asal virus
Pembiakan dan asal virusPembiakan dan asal virus
Pembiakan dan asal virus
 
3 komplikasi transfusi darah
3 komplikasi transfusi darah3 komplikasi transfusi darah
3 komplikasi transfusi darah
 
6 pencatatan & pelapoan bdrs (dr. neni )
6 pencatatan & pelapoan bdrs (dr. neni )6 pencatatan & pelapoan bdrs (dr. neni )
6 pencatatan & pelapoan bdrs (dr. neni )
 
4 keamaman kerja di bdrs
4 keamaman kerja di bdrs4 keamaman kerja di bdrs
4 keamaman kerja di bdrs
 
3 fungsi dan tugas utd & bdrs
3 fungsi dan tugas utd & bdrs3 fungsi dan tugas utd & bdrs
3 fungsi dan tugas utd & bdrs
 
Vektor penyakit cacing (filariasis)
Vektor penyakit cacing (filariasis)Vektor penyakit cacing (filariasis)
Vektor penyakit cacing (filariasis)
 
5b manajemen perawatan dan kalibrasi alat 1
5b manajemen perawatan dan kalibrasi alat 15b manajemen perawatan dan kalibrasi alat 1
5b manajemen perawatan dan kalibrasi alat 1
 
Vektor penyakit virus, riketsia, dan bakteri
Vektor penyakit virus, riketsia, dan bakteriVektor penyakit virus, riketsia, dan bakteri
Vektor penyakit virus, riketsia, dan bakteri
 
Morfologi, daur hidup, perilaku nyamuk
Morfologi, daur hidup, perilaku nyamukMorfologi, daur hidup, perilaku nyamuk
Morfologi, daur hidup, perilaku nyamuk
 
Konsep dasar virologi
Konsep dasar virologiKonsep dasar virologi
Konsep dasar virologi
 

Similar to Hiv

HIV Acquired Immunno Deficiency Syn.pptx
HIV Acquired Immunno Deficiency Syn.pptxHIV Acquired Immunno Deficiency Syn.pptx
HIV Acquired Immunno Deficiency Syn.pptx
Zellanienhd
 
hiv final management -180417201129.pdf
hiv final  management  -180417201129.pdfhiv final  management  -180417201129.pdf
hiv final management -180417201129.pdf
deborayilma
 
hiv / aids final managment -180417201129.pdf
hiv / aids final managment -180417201129.pdfhiv / aids final managment -180417201129.pdf
hiv / aids final managment -180417201129.pdf
deborayilma
 
Hivaids and world today By Dr Anjum Hashmi MPH
Hivaids and world today By Dr Anjum Hashmi MPHHivaids and world today By Dr Anjum Hashmi MPH
Hivaids and world today By Dr Anjum Hashmi MPH
Anjum Hashmi MPH
 
Hiv aids seminar communti
Hiv aids seminar communtiHiv aids seminar communti
Hiv aids seminar communti
Bassam Daqaq
 
HIV infection. HIV-associated related opportunistic infections and invasions
HIV infection. HIV-associated related opportunistic infections and invasionsHIV infection. HIV-associated related opportunistic infections and invasions
HIV infection. HIV-associated related opportunistic infections and invasions
Aniuta Sydorchuk
 
Natural history of HIV/AIDS
Natural history of HIV/AIDSNatural history of HIV/AIDS
Natural history of HIV/AIDS
Dr Kumaravel
 

Similar to Hiv (20)

HIV Acquired Immunno Deficiency Syn.pptx
HIV Acquired Immunno Deficiency Syn.pptxHIV Acquired Immunno Deficiency Syn.pptx
HIV Acquired Immunno Deficiency Syn.pptx
 
Aids Presentation
Aids Presentation Aids Presentation
Aids Presentation
 
introduction to HIV
introduction to HIVintroduction to HIV
introduction to HIV
 
HIV and AIDS
HIV and AIDS HIV and AIDS
HIV and AIDS
 
HIV/AIDS
HIV/AIDSHIV/AIDS
HIV/AIDS
 
352.ppt
352.ppt352.ppt
352.ppt
 
HIV/AIDS (IMMUNOLOGY)
HIV/AIDS (IMMUNOLOGY)HIV/AIDS (IMMUNOLOGY)
HIV/AIDS (IMMUNOLOGY)
 
hivfinal-180417201129.pdf
hivfinal-180417201129.pdfhivfinal-180417201129.pdf
hivfinal-180417201129.pdf
 
HIV/AIDS Management
HIV/AIDS ManagementHIV/AIDS Management
HIV/AIDS Management
 
hiv final management -180417201129.pdf
hiv final  management  -180417201129.pdfhiv final  management  -180417201129.pdf
hiv final management -180417201129.pdf
 
hiv / aids final managment -180417201129.pdf
hiv / aids final managment -180417201129.pdfhiv / aids final managment -180417201129.pdf
hiv / aids final managment -180417201129.pdf
 
Epidemiology of AIDS
Epidemiology of AIDSEpidemiology of AIDS
Epidemiology of AIDS
 
Hivaids and world today By Dr Anjum Hashmi MPH
Hivaids and world today By Dr Anjum Hashmi MPHHivaids and world today By Dr Anjum Hashmi MPH
Hivaids and world today By Dr Anjum Hashmi MPH
 
Hiv dr.tanushka
Hiv dr.tanushkaHiv dr.tanushka
Hiv dr.tanushka
 
Hiv aids seminar communti
Hiv aids seminar communtiHiv aids seminar communti
Hiv aids seminar communti
 
Hiv infection and aids
Hiv infection and aidsHiv infection and aids
Hiv infection and aids
 
HIV infection. HIV-associated related opportunistic infections and invasions
HIV infection. HIV-associated related opportunistic infections and invasionsHIV infection. HIV-associated related opportunistic infections and invasions
HIV infection. HIV-associated related opportunistic infections and invasions
 
hiv and aids
hiv and aidshiv and aids
hiv and aids
 
Hiv In Children
Hiv In ChildrenHiv In Children
Hiv In Children
 
Natural history of HIV/AIDS
Natural history of HIV/AIDSNatural history of HIV/AIDS
Natural history of HIV/AIDS
 

More from riski albughari

More from riski albughari (7)

5 pengawasan dan penilaian kualitas
5 pengawasan dan penilaian kualitas5 pengawasan dan penilaian kualitas
5 pengawasan dan penilaian kualitas
 
1 bagan alur kegiatan bdrs
1 bagan alur kegiatan bdrs1 bagan alur kegiatan bdrs
1 bagan alur kegiatan bdrs
 
Regulasi yan darah 2010
Regulasi yan darah 2010Regulasi yan darah 2010
Regulasi yan darah 2010
 
Cytomegalovirus. nnn
Cytomegalovirus. nnnCytomegalovirus. nnn
Cytomegalovirus. nnn
 
Pemurnian dan identifikasi virus
Pemurnian dan identifikasi virusPemurnian dan identifikasi virus
Pemurnian dan identifikasi virus
 
Serologi
SerologiSerologi
Serologi
 
Serologi ii
Serologi iiSerologi ii
Serologi ii
 

Recently uploaded

Mastering Wealth: A Path to Financial Freedom
Mastering Wealth: A Path to Financial FreedomMastering Wealth: A Path to Financial Freedom
Mastering Wealth: A Path to Financial Freedom
FatimaMary4
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 

Recently uploaded (20)

DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
 
Temporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptx
Temporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptxTemporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptx
Temporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptx
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...
 
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
 
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Mastering Wealth: A Path to Financial Freedom
Mastering Wealth: A Path to Financial FreedomMastering Wealth: A Path to Financial Freedom
Mastering Wealth: A Path to Financial Freedom
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Compare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from homeCompare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from home
 
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
The History of Diagnostic Medical imaging
The History of Diagnostic Medical imagingThe History of Diagnostic Medical imaging
The History of Diagnostic Medical imaging
 
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
 

Hiv

  • 2. Kebanyakan ilmuwan meyakini bahwa AIDS berasal dari Afrika Sub-Sahara selama abad ke-20 kini penyakit pandemik AIDS diperkiraan telah menginfeksi 38,6 juta orang di seluruh dunia. Pada Januari 2006, UNAIDS sebagai badan PBB yang menangani penanggulangan penyakit AIDS dan HIV (Joint United Nations Programme on HIV/AIDS) bekerjasama dengan WHO (World Health Organization), badan PBB untuk kesehatan dunia, memperkirakan AIDS telah membunuh lebih dari 25 juta orang sejak pertama kali diakui pada tanggal 5 Juni 1981. Oleh karena itu, penyakit ini merupakan salah satu wabah paling mematikan dalam sejarah.
  • 3. Pita Merah terlipat sebagai simbol solidaritas untuk orang yang positif terinfeksi virus HIV dan AIDS.
  • 4.
  • 5.
  • 6.
  • 7. The proteins gp120 and gp41 together make up the spikes that project from HIV particles, while p17 forms the matrix and p24 forms the core. Inside the core are three enzymes required for HIV replication called reverse transcriptase, integrase and protease.
  • 8.
  • 9. How can we prove that HIV causes AIDS? Koch's Postulates In the nineteenth century, the German scientist Robert Koch developed a set of four "postulates" to guide people trying to prove that a germ causes a disease. Scientists agree that if HIV satisfies all of these conditions with regard to AIDS then it must be the cause of AIDS:12 Koch 1: The germ must be found in every person with the disease Koch 2: The germ must be isolated from someone who has the disease and grown in pure culture Koch 3: The germ must cause the disease when introduced into a healthy person Koch 4: The germ must be re-isolated from the infected person
  • 10. DESKRIPSIDESKRIPSI •HIV termasuk golongan Retrovirus •Mula-mula dikenal sebagai LAV (Lymphadenopathy Associated Virus), kemudian dikenal sebagai HTLV-III (Human T cell Lymphotropic Virus) dan akhirnya disebut sebagai HIV (Human Immunodeficiency Virus)
  • 11. How many genes does HIV have? •HIV has just nine genes (compared to more than 500 genes in a bacterium, and around 20,000-25,000 in a human). •Three of the HIV genes, called gag, pol and env, contain information needed to make structural proteins for new virus particles. •The other six genes, known as tat, rev, nef, vif, vpr and vpu, code for proteins that control the ability of HIV to infect a cell, produce new copies of virus, or cause disease.
  • 12. What is the difference between HIV-1 and HIV-2? There are two types of HIV: HIV-1 and HIV-2. Both types are transmitted by sexual contact, through blood, and from mother to child, and they appear to cause clinically indistinguishable AIDS. However, it seems that HIV-2 is less easily transmitted, and the period between initial infection and illness is longer in the case of HIV-2.
  • 13.
  • 14.
  • 15. How many subtypes of HIV-1 are there? This diagram illustrates the different levels of HIV classification. Each type is divided into groups, and each group is divided into subtypes and CRFs.
  • 16. Are there differences in transmission? It has been observed that certain subtypes/CRFs are predominantly associated with specific modes of transmission. In particular, subtype B is spread mostly by homosexual contact and intravenous drug use (essentially via blood), while subtype C and CRF A/E tend to fuel heterosexual epidemics (via a mucosal route).
  • 17. UNIQUE CHARASTERISTICS OFUNIQUE CHARASTERISTICS OF RETROVIRUSRETROVIRUS •Virus has enveloped spherical virion that is 80 to 120 nm in diameter and that encloses a capsid containing two copies of the positive-strand RNA genome •RNA dependent DNA polymerase (reverse transcriptase) and integrase enzymes are carried in the virion •Virus receptor is the initial determinant of tissue tropism •Replication proceeds through a DNA intermediate termed the provirus •The provirus integrates randomly into the host chromosome and becomes a celluler gene
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. In this computer generated image, the large object is a human CD4+ white blood cell, and the spots on its surface and the spiky blue objects in the foreground represent HIV particles.
  • 23. This electron microscope photo shows newly formed HIV particles budding from a human cell.
  • 24.
  • 25. DEFINISIDEFINISI AIDSAIDS Penyakit akibat menurunnya daya tahan tubuh yang didapat karena infeksi HIV
  • 26. KLASIFIKASI INFEKSIKLASIFIKASI INFEKSI AIDSAIDS •Kelompok I :Infeksi Akut •Kelompok II :Infeksi kronik asimptomatik •Kelompok III :PGL (Persistent Generalized Lymphadenopathy) •Kelompok IV :Penyakit lain : - Penyakit Neurologis - Penyaakit infeksi sekunder - Keganasan sekunder
  • 27. GEJALA KLINIKGEJALA KLINIK Gejala mayor: •Berat badan menurun lebih dari 10 % dalam 1 bulan •Diare kronis yang berlangsung lebih dari 1 bulan •Demam berkepanjangan lebih dari 1 bulan •Penurunan kesadaran dan gangguan neurologik •Demensia/HIV ensefalopati Gejala minor: •Batuk menetap lebih dari 1 bulan •Dermatitis generalisata •Adanya herpes zoster muli segmental dan herpes zoster berulang •Kandidiasis Orofaringeal •Herpes Simpleks kronis progresif •Limfadenopati generalisata •Infeksi jamur berulang pada alat kelamin wanita •Retinitis virus sitomegalo
  • 28. When to Start Therapy Clinical Category CD4+ Count Viral Load Recommendation Symptomatic (AIDS or severe symptoms) Any value Any value Treat Asymptomatic, AIDS CD4+ < 200/mm3 Any value Treat Asymptomatic CD4+ > 200/mm3 but < 350/mm3 Any value Offer treatment, but controversial † Asymptomatic CD4+ > 350/mm3 > 100,000 c/mL Consider therapy or observe † (Data inconclusive for either alternative) Asymptomatic CD4+ > 350/mm3 < 100,000 c/ml Defer therapy and observe •There are special considerations for pregnant women; consult Pregnancy Tables 1-3 † Patient readiness, probability of adherence, and prognos based on CD4 count and HIV load need to be considered Adult ART Table 1.  
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41. HIV and AIDS in the United Kingdom, 1990-2001
  • 42. . HIV and AIDS in Thailand, 1984-2000
  • 43. DEFINISI KASUS DEWASADEFINISI KASUS DEWASA Seorang dewasa (>12 tahun) dianggap AIDSSeorang dewasa (>12 tahun) dianggap AIDS apabila menunjukkan tes HIV positif denganapabila menunjukkan tes HIV positif dengan strategi pemeriksaan yang sesuai dengan se-strategi pemeriksaan yang sesuai dengan se- kurang2nya didapatkankurang2nya didapatkan 2 gejala mayor2 gejala mayor dandan 1 gejala minor1 gejala minor,, dan gejala ini bukan disebabkandan gejala ini bukan disebabkan oleh keadaan lain yang tidak berkaitanoleh keadaan lain yang tidak berkaitan dengan infeksi HIVdengan infeksi HIV
  • 44. DEFINISI KASUS ANAKDEFINISI KASUS ANAK  Anak umur lebih dari 18 bulan,menunjukkan tes HIV positif,Anak umur lebih dari 18 bulan,menunjukkan tes HIV positif, dan sekurang-kurangnya didapatdan sekurang-kurangnya didapat -2 gejala mayor dan 2 gejala minor dibawah ini dengan ibu-2 gejala mayor dan 2 gejala minor dibawah ini dengan ibu HIV positif, dan gejala tersebut bukan disebabkan olehHIV positif, dan gejala tersebut bukan disebabkan oleh keadaan lain yang tidak berkaitan dengan infeksi HIVkeadaan lain yang tidak berkaitan dengan infeksi HIV  Anak umur 18 bulan atau kurang, ditemukanAnak umur 18 bulan atau kurang, ditemukan -2 gejala mayor yang-2 gejala mayor yang berkaitanberkaitan dan 2 gejala minor dengandan 2 gejala minor dengan ibu HIV positif, dan gejala tersebut bukan disebabkan olehibu HIV positif, dan gejala tersebut bukan disebabkan oleh keadaan lain yang tidak berkaitan dengan infeksi HIVkeadaan lain yang tidak berkaitan dengan infeksi HIV
  • 45. GEJALA MAYOR • Berat badan menurun atau gagal tumbuh •Diare terus menerus atau berulang dalam waktu lebih 1 bulan •Demam terus menerus atau berulang > 1 bulan •Infeksi saluran pernafasan bagian bawah yang parah atau menetap GEJALA MINOR •Limfadenopati generalisata atau hepatosplenomegali •Kandidiasis oral •Infeksi bakteridan/virus yang berulang •Batuk kronis •Dermatitis yang luas •Ensefalitis
  • 46. CARA PENULARANCARA PENULARAN 1. Hubungan seksual 2. Kontak langsung dengan darah/ produk darah/ jarum suntik 3.Vertikal
  • 47. GOLONGAN RESIKO TINGGIGOLONGAN RESIKO TINGGI 1. Sering berganti pasangan seksual 2. PMS (Penyakit Menular Seksual Wanita Tuna Susila 3. Penyalahgunaan obat (pemakai narkoba suntikan)
  • 48. PEMERIKSAAN LABORATORIUM IPEMERIKSAAN LABORATORIUM I (spesifik HIV)(spesifik HIV) •Dipstick •ELISA •Western Blot: p24, gp41, gp 120 •RT-PCR
  • 49. PEMERIKSAAN LABORATORIUM IIPEMERIKSAAN LABORATORIUM II 1. Pemeriksaan laboratorium dasar •Pemeriksaan darah lengkap, termasuk hitung jenis •Tes faal ginjal •Tes faal hepar 2. Menentukan tahapan infeksi •Jumlah CD4 atau persentase limfosit atau viral load 3. Pemeriksaan Tambahan •Foto toraks •VDRL •IgG anti Toxoplasma •HBsAg/anti HBs/HBcAg, anti HCV
  • 50. Such measurements can be made using PCR, branched-DNA signal-amplification (bDNA) or quantitative microculture techniques. For example, the table below shows just how useful bDNA forecasts can be:68 Viral load (RNA copies per millilitre of blood plasma) Proportion of patients developing AIDS within six years less than 500 5.4% 501-3,000 16.6% 3,001-10,000 31.7% 10,001-30,000 55.2% more than 30,000 80.0%
  • 51. The immune deficiency definition of AIDS requires a CD4+ cell count consistently below 200 cells per cubic millimetre of blood, which cannot be explained by any factor other than HIV (such as cancer, malnutrition, radiation or chemotherapy).
  • 52. •treatment of adults and adolescents •treatment of children •treatment of pregnant women and prevention of mother-to-child transmission of HIV •prevention of opportunistic infections Treatment
  • 53. Opportunistic infections: Infections that usually don't cause disease in people with normal immune systems, but can affect people with damaged immune systems, including people with HIV.
  • 54. Topics covered in the guidelines include: •the goals of anti-HIV therapy •when to start treatment •monitoring of patient health •medication side effects and their management •anti-HIV medications for use during pregnancy •diagnosis of HIV infection in infants
  • 55. Antiretroviral Agents Currently Available (generic name/Trade name) Nucleoside Analogs zidovudine/Retrovir (AZT, ZDV) didanosine/Videx, Videx EC (ddI) zalcitabine/HIVID (ddC) stavudine/Zerit (d4T) lamivudine/Epivir (3TC) abacavir/Ziagen (ABC) Non-Nucleoside Reverse Transcriptase Inhibitors nevirapine/Viramune (NVP) delavirdine/Rescriptor (DLV) efavirenz/Sustiva (EFV) Nucleotide Analogue tenofovir DF/Viread (TDF) Protease Inhibitors indinavir/Crixivan ritonavir/Norvir saquinavir/Invirase, Fortovase nelfinavir/Viracept amprenavir/Agenerase lopinavir/ritonavir, Kaletra